Welcome to Flow Pharma Inc.

Page Loading...

Menu
blob-1
blob-2

Our Mission

Flow Pharma is dedicated to immunotherapy innovation.

Our exclusive technology and manufacturing expertise are poised to transform the treatment and prevention of cancer and viral disease.

Subscribe to Flow Pharma Updates



background

Flovid-20

Flovid-20

An inhaled treatment to prevent COVID-19 disease in both virus-exposed and healthy patient populations..

FlowVax Ebola & Marburg

Ebola, Marburg

Marburg is a weaponized Ebola-like virus. By stimulating T-cells to target this virus, long-lasting infection prevention is attainable.

FlowVax BreastCA

Cancer

A revolutionary T-cell biomedicine that provides new hope for those with treatment-resistant, triple-negative breast cancer.

FlowVax HPV

Cancer, HPV

A targeted T-cell immunotherapy for HPV-induced squamous cell carcinoma of the head, neck, and cervix.

News & Press

Delta and Omicron Variants are Driving New Cases

Uncategorized

During the COVID-19 pandemic, new cases in the U.S. have repeatedly risen and dropped dramatically.

More Evidence for T-Cells: Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts

COVID-19

A new research paper led by the Imperial College London, published in the peer-reviewed journal nature communications, finds the following:.

The Peer Reviewed Journal Vaccines Published the Results of Flow Pharma’s COVID-19 Primate Study

Company Update, COVID-19, FLOVID-20

Flow Pharma, Inc., a San Francisco Bay Area biotechnology company developing the FlowVax™ peptide vaccine platform technology, today announced the publication of an article describing research performed at the University of Texas Medical Branch at Galveston (UTMB)

Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies

Research Publications

In December 2019, a novel coronavirus, termed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of pneumonia with severe respiratory distress and outbreaks in Wuhan, China.